The collaboration will produce an independently evaluated evidence base and peer-reviewed white paper supporting U.S. growth for the FDA-cleared autonomic nervous system diagnostic
Most promising health products don’t fail because the science is wrong. They fail in the unglamorous middle — the licensing conversations, regulatory timelines, and launch sequencing that turn an idea into something a patient can actually use. Women’s health, a sector finally attracting serious founders and capital, is about to discover how many of its startups can survive that middle.
This report presents HITLAB’s independent evaluation of the Evida Health's AI platform, an AI that transforms clinical registry abstraction and quality reporting through intelligent automation, evidence-linked insights, and real- time performance visibility.
Immunotherapy resistance remains a critical limitation in oncology, particularly in microsatellite stable (MSS) tumors. ENB-003, a first-in-class selective endothelin B receptor (ETBR) inhibitor, targets immune exclusion by restoring T-cell trafficking into tumors.
Colon cancer remains one of the most preventable yet under- detected cancers in the United States, particularly among underserved communities. HITLAB is conducting this marketing and impact study on behalf of Grapevine Health to assess the effectiveness of a six-part colon cancer screening health literacy
video series.
